GenFleet Therapeutics (Shanghai) (HAM:Y3L) Beneish M-Score: -6.39 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Y3L GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
19 GF Score
Price €2.92
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) Beneish M-Score?

GenFleet Therapeutics (Shanghai) HAM:Y3L -2.80% 19 Beneish M-Score is -6.39 as of Aug. 04, 2026. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 822 Biotechnology companies, GenFleet Therapeutics (Shanghai) ranks better than 97.08% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -6.39 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for GenFleet Therapeutics (Shanghai)'s Beneish M-Score or its related term are showing as below:

HAM:Y3L' s Beneish M-Score Range Over the Past 10 Years
Min: -6.39   Med: -6.39   Max: -6.39
Current: -6.39

During the past 3 years, the highest Beneish M-Score of GenFleet Therapeutics (Shanghai) was -6.39. The lowest was -6.39. And the median was -6.39.

GenFleet Therapeutics (Shanghai) Beneish M-Score Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) Beneish M-Score Chart

GenFleet Therapeutics (Shanghai) Annual Data
Trend Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 -6.39

GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score 0.00 0.00 0.00 0.00 -6.39

HAM:Y3L vs VRTX, REGN, RVMD: Beneish M-Score Comparison

For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GenFleet Therapeutics (Shanghai) Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s Beneish M-Score distribution charts can be found below:

* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s Beneish M-Score falls into.


HAM:Y3L
19GF Score
GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenFleet Therapeutics (Shanghai) Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of GenFleet Therapeutics (Shanghai) for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1367+0.528 * 1.2582+0.404 * 0.3147+0.892 * 1.1501+0.115 * 1.0889
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1263+4.679 * -0.755526-0.327 * 0.042
=-6.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €2.57 Mil.
Revenue was €15.80 Mil.
Gross Profit was €10.14 Mil.
Total Current Assets was €262.08 Mil.
Total Assets was €266.22 Mil.
Property, Plant and Equipment(Net PPE) was €2.64 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.18 Mil.
Selling, General, & Admin. Expense(SGA) was €9.87 Mil.
Total Current Liabilities was €44.80 Mil.
Long-Term Debt & Capital Lease Obligation was €1.40 Mil.
Net Income was €-217.59 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €-16.45 Mil.
 Total Receivables was €16.34 Mil.
Revenue was €13.73 Mil.
Gross Profit was €11.10 Mil.
Total Current Assets was €74.54 Mil.
Total Assets was €79.60 Mil.
Property, Plant and Equipment(Net PPE) was €3.64 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.85 Mil.
Selling, General, & Admin. Expense(SGA) was €7.62 Mil.
Total Current Liabilities was €327.06 Mil.
Long-Term Debt & Capital Lease Obligation was €1.83 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.569 / 15.795) / (16.34 / 13.734)
=0.162646 / 1.189748
=0.1367

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(11.098 / 13.734) / (10.144 / 15.795)
=0.808068 / 0.642229
=1.2582

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (262.084 + 2.64) / 266.22) / (1 - (74.536 + 3.639) / 79.596)
=0.005619 / 0.017853
=0.3147

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=15.795 / 13.734
=1.1501

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.851 / (1.851 + 3.639)) / (1.184 / (1.184 + 2.64))
=0.337158 / 0.309623
=1.0889

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(9.868 / 15.795) / (7.618 / 13.734)
=0.624755 / 0.554682
=1.1263

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.397 + 44.801) / 266.22) / ((1.833 + 327.06) / 79.596)
=0.173533 / 4.132029
=0.042

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-217.59 - 0 - -16.454) / 266.22
=-0.755526

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

GenFleet Therapeutics (Shanghai) has a M-score of -6.51 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -6.39 mean?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Beneish M-Score of -6.39 as of Aug. 04, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. According to the industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #24 out of 822 companies in the Biotechnology industry, placing it in the top 2.9%.
Is GenFleet Therapeutics (Shanghai)'s Beneish M-Score too high?
GenFleet Therapeutics (Shanghai)'s current Beneish M-Score is -6.39. Based on the distribution chart, GenFleet Therapeutics (Shanghai) ranks #24 out of 822 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #24 out of 822 companies for Beneish M-Score. This places GenFleet Therapeutics (Shanghai) in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current Beneish M-Score is -6.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Beneish M-Score of -6.39. The current Beneish M-Score is -6.39. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Beneish M-Score is -6.39 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges 02595:Hong Kong
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score

Get the complete analysis for HAM:Y3L

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price